Caitlin W Elgarten1,2, Ceylan Tanes3, Jung-Jin Lee3, Lara A Danziger-Isakov4, Michael S Grimley5, Michael Green6, Marian G Michaels6, Jessie L Barnum7, Monica I Ardura8, Jeffery J Auletta8,9,10, Jesse Blumenstock2, Alix E Seif1,2, Kyle L Bittinger3,11, Brian T Fisher2,12. 1. Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2. Center for Pediatric Clinical Effectiveness Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 3. PennCHOP Microbiome Program, Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA. 4. Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital, Medical Center and University of Cincinnati, Cincinnati, Ohio, USA. 5. Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, Ohio, USA. 6. Division of Infectious Diseases, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA. 7. Division of Blood and Marrow Transplantation, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA. 8. Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio, USA. 9. Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio, USA. 10. National Marrow Donor Program/Be The Match, Minneapolis, Minnesota, USA. 11. Division of Gastroenterology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 12. Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: The contribution of the gastrointestinal tract microbiome to outcomes after allogeneic hematopoietic cell transplantation (HCT) is increasingly recognized. Investigations of larger pediatric cohorts aimed at defining the microbiome state and associated metabolic patterns pretransplant are needed. METHODS: We sought to describe the pretransplant stool microbiome in pediatric allogenic HCT patients at four centers. We performed shotgun metagenomic sequencing and untargeted metabolic profiling on pretransplant stool samples. Samples were compared with normal age-matched controls and by clinical characteristics. We then explored associations between stool microbiome measurements and metabolite concentrations. RESULTS: We profiled stool samples from 88 pediatric allogeneic HCT patients, a median of 4 days before transplant. Pretransplant stool samples differed from healthy controls based on indices of alpha diversity and in the proportional abundance of specific taxa and bacterial genes. Relative to stool from healthy patients, samples from HCT patients had decreased proportion of Bacteroides, Ruminococcaeae, and genes involved in butyrate production, but were enriched for gammaproteobacterial species. No systematic differences in stool microbiome or metabolomic profiles by age, transplant indication, or hospital were noted. Stool metabolites demonstrated strong correlations with microbiome composition. DISCUSSION: Stool samples from pediatric allogeneic HCT patients demonstrate substantial dysbiosis early in the transplant course. As microbiome disruptions associate with adverse transplant outcomes, pediatric-specific analyses examining longitudinal microbiome and metabolome changes are imperative to identify causal associations and to inform rational design of interventions.
BACKGROUND: The contribution of the gastrointestinal tract microbiome to outcomes after allogeneic hematopoietic cell transplantation (HCT) is increasingly recognized. Investigations of larger pediatric cohorts aimed at defining the microbiome state and associated metabolic patterns pretransplant are needed. METHODS: We sought to describe the pretransplant stool microbiome in pediatric allogenic HCT patients at four centers. We performed shotgun metagenomic sequencing and untargeted metabolic profiling on pretransplant stool samples. Samples were compared with normal age-matched controls and by clinical characteristics. We then explored associations between stool microbiome measurements and metabolite concentrations. RESULTS: We profiled stool samples from 88 pediatric allogeneic HCT patients, a median of 4 days before transplant. Pretransplant stool samples differed from healthy controls based on indices of alpha diversity and in the proportional abundance of specific taxa and bacterial genes. Relative to stool from healthy patients, samples from HCT patients had decreased proportion of Bacteroides, Ruminococcaeae, and genes involved in butyrate production, but were enriched for gammaproteobacterial species. No systematic differences in stool microbiome or metabolomic profiles by age, transplant indication, or hospital were noted. Stool metabolites demonstrated strong correlations with microbiome composition. DISCUSSION: Stool samples from pediatric allogeneic HCT patients demonstrate substantial dysbiosis early in the transplant course. As microbiome disruptions associate with adverse transplant outcomes, pediatric-specific analyses examining longitudinal microbiome and metabolome changes are imperative to identify causal associations and to inform rational design of interventions.
Authors: John S Tanaka; Rebecca R Young; Sarah M Heston; Kirsten Jenkins; Lisa P Spees; Anthony D Sung; Kelly Corbet; Jillian C Thompson; Lauren Bohannon; Paul L Martin; Andre Stokhuyzen; Richard Vinesett; Doyle V Ward; Shakti K Bhattarai; Vanni Bucci; Mehreen Arshad; Patrick C Seed; Matthew S Kelly Journal: Biol Blood Marrow Transplant Date: 2020-07-17 Impact factor: 5.742
Authors: Lindsey E Romick-Rosendale; David B Haslam; Adam Lane; Lee Denson; Kelly Lake; Alyss Wilkey; Miki Watanabe; Stuart Bauer; Bridget Litts; Nathan Luebbering; Christopher E Dandoy; Stella M Davies Journal: Biol Blood Marrow Transplant Date: 2018-07-26 Impact factor: 5.742
Authors: Jonathan U Peled; Sean M Devlin; Anna Staffas; Melissa Lumish; Raya Khanin; Eric R Littmann; Lilan Ling; Satyajit Kosuri; Molly Maloy; John B Slingerland; Katya F Ahr; Kori A Porosnicu Rodriguez; Yusuke Shono; Ann E Slingerland; Melissa D Docampo; Anthony D Sung; Daniela Weber; Amin M Alousi; Boglarka Gyurkocza; Doris M Ponce; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Ying Taur; Eric G Pamer; Robert R Jenq; Marcel R M van den Brink Journal: J Clin Oncol Date: 2017-03-15 Impact factor: 44.544
Authors: Hedvig E Jakobsson; Cecilia Jernberg; Anders F Andersson; Maria Sjölund-Karlsson; Janet K Jansson; Lars Engstrand Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Ernst Holler; Peter Butzhammer; Karin Schmid; Christian Hundsrucker; Josef Koestler; Katrin Peter; Wentao Zhu; Daniela Sporrer; Thomas Hehlgans; Marina Kreutz; Barbara Holler; Daniel Wolff; Matthias Edinger; Reinhard Andreesen; John E Levine; James L Ferrara; Andre Gessner; Rainer Spang; Peter J Oefner Journal: Biol Blood Marrow Transplant Date: 2014-01-31 Impact factor: 5.742
Authors: Nathan D Mathewson; Robert Jenq; Anna V Mathew; Mark Koenigsknecht; Alan Hanash; Vincent B Young; Subramaniam Pennathur; Marcel van den Brink; Tomomi Toubai; Katherine Oravecz-Wilson; Shin-Rong Wu; Yaping Sun; Corinne Rossi; Hideaki Fujiwara; Jaeman Byun; Yusuke Shono; Caroline Lindemans; Marco Calafiore; Thomas M Schmidt; Kenya Honda; Pavan Reddy Journal: Nat Immunol Date: 2016-03-21 Impact factor: 25.606